Cytiva, a Danaher company and global life sciences leader, has completed significant expansion projects in several locations in the United States, Europe, and Asia as part of its ongoing commitment to enhancing delivery for customers developing and manufacturing advanced therapeutics. Set to continue through 2028, these expansions will meet increased customer demand as part of Cytiva’s long-term growth plan and in-region manufacturing strategy, supported by an investment of USD 1.6 billion since 2019.
Customers now benefit from faster delivery across Cytiva’s portfolio, including chromatography resins, filtration, single-use bags and cell culture media.
Pierre-Alain Ruffieux, Chief Operating Officer at Cytiva, says: “A robust supply chain is critical to our customers so they can deliver life-changing therapies to patients around the world. We have increased our global manufacturing capacity, with a focus on in-region for-region, to meet the demands and best serve the customer.”
The latest investments in chromatography resins and filtration include:
- Approximately double production capacity of chromatography resins manufacturing in Uppsala, Sweden with the addition of new factories, new equipment, as well as improved automation capabilities and a new tank farm for solvent storage.
- Investment in chromatography resins reserves in Sweden to support customers with short-term emergency needs.
- Enhanced local supply in North America with the construction of a second resins manufacturing site with approximately 100 full-time associates in Muskegon, Michigan, now. The site is slated to be fully operational with plans to hire about 100 more associates by end of 2028.
Comments powered by CComment